Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers 1 (PDF 7.97 MB)

  Published:

  15 November 2023

• Appraisal consultation committee papers 2 (PDF 2.35 MB)

  Published:

  15 November 2023

• Final appraisal determination committee papers (PDF 2.59 MB)

  Published:

  15 November 2023